EICHORPublic-registry trials using Survodutide that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Survodutide appears in 1 registered trial Eichor's radar has found, sponsored by Boehringer Ingelheim, the most recent registered as Phase 3, with a planned enrollment of 600. Registered timeline: 2026–2028. The registry holds 11,837 registered studies for Type 2 Diabetes.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | Boehringer Ingelheim | Type 2 Diabetes | PHASE3 | 115 |
| Status | Not Yet Recruiting · planned start 2026-08 |
| Primary completion | 2028-01 |
| Enrollment target | 600 participants |
| Design | Randomized · Parallel · Phase 3 · 9 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 115 listed in Australia, Canada, India, New Zealand |
All fields verbatim from the ClinicalTrials.gov record for NCT07754461.
| First registered study | December 2020 — NCT04667377 (Boehringer Ingelheim) |
| Registered studies matching this name | 25 all-time · 3 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 11,837 registered studies for Type 2 Diabetes. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Type 2 Diabetes drugs
← Eichor home · All tracked trials · Type 2 Diabetes studies · Weekly briefs
